Samsung Electronics Shares Jump on HBM4 Mass Production Report 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
SEATTLE, Jan. 08, 2018 -- Stratos Genomics, Inc., a 4th generation DNA sequencing technology company, today announced it has raised $20 million in venture capital from Fisk Ventures. The funds will be used for final system development leading to commercial introduction of the company’s proprietary sequencing platform. The next phase of system development will build upon recent breakthroughs in Stratos Genomics’ biochemistry development program which will enable the company’s Sequencing by Expansion (SBX™) technology to perform sequencing at commercially compelling levels of read length, accuracy, process speed and work flow efficiency.
SBX is an elegant, low-cost sequencing technology, with a simple workflow and rapid sample-to-measurement process times that can be configured for small, targeted sequence applications as well as large high-throughput whole genome systems. The versatile, low-cost SBX sequencing technology will enable opportunities for a vast array of growing market applications.
“We are excited that our vision of introducing a transformative next generation sequencing platform to the healthcare and research markets is approaching realization,” Stratos Genomics President & CEO, Mark Kokoris, said. “Our recent development breakthroughs put us in position to evaluate a number of strategic options and open discussions with partners who share our vision.”
About Stratos Genomics
Stratos Genomics’ goal is to establish the next gold standard of DNA sequencing with its flagship Sequencing by Expansion (SBX™) method. SBX is a 4th generation DNA sequencing method that uses a simple biochemical reaction to encode the sequence of a DNA molecule into a highly measurable surrogate polymer called an Xpandomer. Xpandomers encode the sequence information in high signal-to-noise reporters that enable high-fidelity, single molecule sequencing in a low-cost nanopore instrument. The entire process time from DNA sample to nanopore measurement is < 1 hour, enabling rapid diagnostics and treatment. By eliminating sample prep overhead required by other technologies and fully leveraging single molecule measurement efficiencies, SBX enables a new path forward for next generation sequencing applications. A versatile and simple workflow is key to delivering timely and accurate, targeted DNA sequence at the lowest price point.
Media Contact:
Mark Kokoris
President & CEO
[email protected]
(206) 576-7320
